Corbus Pharmaceuticals
CRBP
111 hedge funds and large institutions have $185M invested in Corbus Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 18 reducing their positions, and 17 closing their positions.
236% more call options, than puts
Call options by funds: $6.89M | Put options by funds: $2.05M
144% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 18
53% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 17
10% more capital invested
Capital invested by funds: $168M → $185M (+$17M)
6% more funds holding
Funds holding: 105 → 111 (+6)
0.04% more ownership
Funds ownership: 1.59% → 1.62% (+0.04%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.68M |
| 2 |
PA
Pinnacle Associates
New York
|
+$6.9M |
| 3 |
CG
Carmignac Gestion
Paris,
France
|
+$4.12M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.25M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$12.5M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.47M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$682K |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$366K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$314K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Barclays
London,
United Kingdom
| – | -$169 | -1 | -25% |
|
CRBP Hedge Fund Activity: Q1 2020 in Review
111 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2020, worth a combined $185M — up 10% from $168M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CRBP positions and 17 closed out — a net gain of 9 holders — while 44 added to existing stakes and 18 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.68M. The largest seller was ETF Managers Group, cutting an estimated $12.5M.
- 111 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2020, up from 105 in Q4 2019.
- Funds reported $185M of Corbus Pharmaceuticals stock for Q1 2020, up 10% quarter-over-quarter.
- 26 funds opened new Corbus Pharmaceuticals positions in Q1 2020 and 17 closed out, a net change of +9 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2020 was Citadel Advisors, an estimated $7.68M added.
- The largest Corbus Pharmaceuticals seller in Q1 2020 was ETF Managers Group, an estimated $12.5M sold.
Based on aggregated 13F filings for Q1 2020.